The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents

Inclusion Criteria: 1. Age≤18 years old, gender no limited. 2. Patients with acute lymphoblastic leukemia diagnosed by bone marrow pathology or cytology. 3. Plan to receive CAM (cyclophosphamide,cytarabine,6-MP)chemotherapy regimen. 4. Previously not received radiotherapy. 5. Karnofsky Performance Scores ( KPS)≥60. 6. The expected survival time was \>3 months. 7. Neutropenia or agranulocytosis, no bleeding tendency. 8. No significant cardiac dysfunction or metabolic disease. 9. TBIL(total bilirubin ), ALT（alanine aminotransferase）,AST（glutamic-oxalacetic transaminase） \< 2.5×ULN（upper limit of normal）. 10. BUN（blood urine nitrogen），Cr（creatinine），UA（uric acid）\<1.5×ULN. 11. Written informed consent are acquired. Exclusion Criteria: 1. With a history of systemic radiotherapy. 2. Infection difficult to control, the body temperature ≥ 38℃. 3. Other situation that investigators consider as contra-indication for this study.